Unfractionated heparin (UFH) is a widely used anticoagulant, particularly in critical care settings, to prevent and treat thromboembolic disorders. Monitoring UFH therapy is crucial to ensure ...

Up until the 1950s, scientists were scratching their heads trying to figure out why their experiments using perfectly healthy ...

[8] reported that physicians treating patients for pulmonary embolism and deep-vein thrombosis frequently underdosed their patients and were slow to change their heparin therapy. Sixty percent of ...

Heparin-induced thrombocytopenia ... The study was designed to reflect conventional clinical practice, whereby treatment of patients with HIT was initiated upon clinical suspicion.

Heparin-induced thrombocytopenia (HIT) can be a serious complication of unfractionated heparin therapy. There are two types of HIT: Type I HIT: This form is non-immune mediated. Thrombocytopenia ...

Lifelong therapy using 81 mg to 325 mg daily should ... with STEMI unless a contraindication exists. Unfractionated heparin, low-molecular-weight heparin (enoxaparin or fondaparinux) or ...

The short DNA sequence in purple, [M08s G2]c, is the antidote to prevent severe bleeding in the treatment using the bispecific aptamer Pse08-29 for heparin-induced thrombocytopenia.

Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and ...